Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Vivos Therapeutics ( (VVOS) ) has issued an announcement.
On February 14, 2025, Vivos Therapeutics, Inc. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., allowing the company to sell shares of its common stock valued up to $3,328,881 through the Nasdaq Capital Market. This move is part of the company’s strategy to raise capital, with Wainwright acting as the sales agent under specific conditions and commission agreements. Additionally, the company amended employment agreements for its CEO and CFO, effective January 1, 2025, as part of an ongoing effort to align executive compensation with company goals.
More about Vivos Therapeutics
Vivos Therapeutics operates in the healthcare industry, focusing on the development of innovative treatments for sleep apnea and related disorders. The company primarily provides therapeutic products and services aimed at improving the health and wellness of its patients.
Average Trading Volume: 242,649
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $25.03M
Learn more about VVOS stock on TipRanks’ Stock Analysis page.
